Fifth Third Bancorp’s Tvardi Therapeutics TVRD Stock Holding History

Fifth Third Bancorp’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2	Hold	1	–	–	﹤0.01%	4336
2026 Q1	$3	Buy	+1	New	+$4	﹤0.01%	4301
2023 Q2	–	Sell	-15	Closed	-$2.64K	–	2791
2023 Q1	$2.64K	Buy	+15	New	+$5.02K	﹤0.01%	2506
2021 Q4	–	Sell	-1	Closed	–	–	2814
2021 Q3	$0	Buy	+1	New	+$502	﹤0.01%	2773
2021 Q2	–	Sell	-24	Closed	-$19K	–	2550
2021 Q1	$19K	Hold	24	–	–	﹤0.01%	1804
2020 Q4	$13K	Hold	24	–	–	﹤0.01%	1848
2020 Q3	$11K	Hold	24	–	–	﹤0.01%	1756
2020 Q2	$15K	Hold	24	–	–	﹤0.01%	1638
2020 Q1	$11K	Buy	+24	New	+$13K	﹤0.01%	1695

Other funds holding TVRD

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AFG

American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Fifth Third Bancorp's TVRD Position: Q2 2026 in Review

Fifth Third Bancorp held its Tvardi Therapeutics (TVRD) position steady in Q2 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #4336.

Fifth Third Bancorp first reported a position in TVRD in Q1 2020 and has held it in 9 quarters since. The position peaked at $19K in Q1 2021. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

Fifth Third Bancorp held 1 share of Tvardi Therapeutics worth $2 as of Q2 2026.
Fifth Third Bancorp left its Tvardi Therapeutics share count unchanged in Q2 2026.
Tvardi Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #4336 holding.
Fifth Third Bancorp first reported a position in Tvardi Therapeutics in Q1 2020 and has held it in 9 quarters since.
Fifth Third Bancorp's Tvardi Therapeutics position peaked at $19K in Q1 2021.
58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.